The decision follows a similar move undertaken in the US market in 2016.
It applies to drugs that are also used in human medicine, called Highest Priority Critically Important Antimicrobials (HPCIA) by the World Health Organization (WHO).
"Starting in 2018, we will begin implementing a new broiler chicken antibiotics policy in markets around the world," the company said in a statement issued yesterday.
By 2018, HPCIAs will be eliminated in broiler chicken for the Brazil, Canada, Japan, South Korea, the US, and Europe. An exception will be made for the antibiotic colistin for Europe only.
It will be fully implemented globally by January 2027, although the firm said: "Our goal is to have this policy implemented before this date."
Scientists have for decades argued there is a link between antibiotic use in animals and the dwindling effectiveness of these drugs in human medicine.
Industrial-scale poultry farmers often use antibiotics not to treat outbreaks of disease in their flocks but to prevent it from occurring.
Some also use the drugs to help birds gain weight more quickly. Certain antibiotics destroy bacteria in the gut, which means that the chicken can convert feed to muscle faster.
According to the Centers for Disease Control and Prevention (CDC), at least two million people in the US become infected with bacteria that are resistant to antibiotics every year, leading to 23,000 deaths.
According to some estimates, drug-resistant bacteria may within decades be causing more deaths than cancer.
The US Consumers Union, a non-profit advocacy group, hailed the decision.
"The widespread use of antibiotics on livestock that aren't sick is contributing to a global public health crisis with potentially dire consequences," said Jean Halloran, director of the organization's food policy initiatives.
The WHO's list of HCIAs falls into five categories: quinolones; third-generation cephalosporins; macrolides and ketolides; glycopeptides; and polymyxins.
These drugs are notably frontline medications in the fight against salmonella, enterobacter and E. Coli infections.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
